Measurement of in vivo glucose transport from blood to tissue of experimentally-induced glioma in rat brain

Mies, Günter

doi:10.1007/bf00172453

Cited by 8 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a contrasting situation, brain tumors, which usually lack a barrier, have high glucose utilization rates. It is believed that glucose transport across tumor endothelium is not coupled to tumor glucose demand (Mies, 1992), and in aggressive tumors the GLUT-1 is infrequently expressed (Guerin et al, 1992;Harik and Roessmann, 1991). Other situations where the glucose transporter has been shown to be downregulated includes experimental diabetes and Alzheimer disease (Kalaria and Harik, 1989).…”

Section: Glut-1 Expression In Neural Transplantsmentioning

confidence: 99%

Immunocytochemical expression of the blood—brain barrier glucose transporter (GLUT‐1) in neural transplants and brain wounds

Rosenstein

1994

J of Comparative Neurology

View full text Add to dashboard Cite

The present study examined the immunocytochemical expression of the blood-brain barrier glucose transporter (GLUT-1) in a series of fetal neocortical transplants, autonomic tissue transplants, and stab wounds to the rat brain. GLUT-1 is one of a family of different glucose transporters and is found exclusively on barrier-type endothelial cells. In the brain it is responsible for the regulated facilitative diffusion of glucose across the blood-brain barrier. This investigation is the first to determine if this important molecule is altered during the process of angiogenesis that occurs following neural transplantation procedures or direct brain injury. Beginning in late fetal brain, e.g., E18 and continuing into maturity, GLUT-1 was strongly and exclusively expressed on normal cerebral vessels. In solid fetal central nervous system (CNS) transplants up to around 3 weeks postoperative, GLUT-1 was only weakly expressed, particularly as exemplified by colloidal gold immunostaining when compared with the host. At later times examined, up to 15 months postoperative, GLUT-1 immunoexpression was comparable with the normal adjacent brain. In autonomic tissue transplants, where the vessels do not have a blood-brain barrier, as expected, GLUT-1 was not expressed. In stab wounds, at 1 week there was extensive gliosis, and the injured vessels appeared fragmented and collapsed but still expressed GLUT-1, although to a somewhat lesser extent than normal brain. Between 3 and 6 weeks, GLUT-1 was expressed on tortuous vessels and in apparently fibrillar processes in the wound vicinity with a similar pattern to astrocyte (GFAP) reactivity. These results suggest the occurrence of a down-regulation of GLUT-1 in early transplants, perhaps related to reduced glycolytic activity or transient ischemia, or possibly due to the utilization of alternative energy sources. That GLUT-1 expression was not entirely lost in stab wounds to the mature brain suggests that the protein may be more labile in fetal or perinatal brain than in the adult and may not be affected by direct injury. Coupled with previous transplantation studies that have shown reduced neuronal glycolysis and potential barrier alterations, the reduction of GLUT-1 activity within nearly the identical time frame could indicate a relatively early critical period in cellular metabolism following transplantation of CNS tissue.

show abstract

Section: Glut-1 Expression In Neural Transplantsmentioning

confidence: 99%

Immunocytochemical expression of the blood—brain barrier glucose transporter (GLUT‐1) in neural transplants and brain wounds

Rosenstein

1994

J of Comparative Neurology

View full text Add to dashboard Cite

show abstract

“…Die Höhe des Tumorstoffwechsels kann durch relativ quantifizierende Verfahren (z. B. Tumor/Non-Tumor-Quotient) bestimmt werden, jedoch erlaubt die Tumorbiologie in der Regel keine ausreichend valide, absolut quantitative Abschätzung der Glukosemetabolisierungsrate in µmol/100 g/min mittels mathematischer Modelle [42].…”

Section: Pet Und Spectunclassified

Pr�operative Bildgebung

et al. 2004

View full text Add to dashboard Cite

With the progressive development of soft- and hardware, the acceptance of image-guided neurosurgery has increased dramatically. Additional image data are required to analyze the nature and the dimensions of pathological processes and the surrounding tissue. In this context, fMRI, SPECT, PET, as well as special modalities of CT and MR imaging, are routinely used. Secondary post-processing options are used to detect intracerebral lesions as well as adjacent functional eloquent regions in the parenchymatous organ pre- and intraoperatively. The integration of different image information guarantees the precise planning and realization of surgical maneuvers. The segmentation of interesting structures and risk structures, as well as their implementation in the neuronavigation systems, help to avoid additional intraoperative traumatization and offer a higher level of safety and precision. In this article the value and limitations of presurgical imaging will be discussed.

show abstract

Anatomical and biochemical investigation of primary brain tumours

Sole

Falini

Ravasi³

et al. 2001

Eur J Nucl Med

View full text Add to dashboard Cite

Cancerous transformation entails major biochemical changes including modifications of the energy metabolism of the cell, e.g. utilisation of glucose and other substrates, protein synthesis, and expression of receptors and antigens. Tumour growth also leads to heterogeneity in blood flow owing to focal necrosis, angiogenesis and metabolic demands, as well as disruption of transport mechanisms of substrates across cell membranes and other physiological boundaries such as the blood-brain barrier. All these biochemical, histological and anatomical changes can be assessed with emission tomography, X-ray computed tomography (CT), magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Whereas anatomical imaging is aimed at the diagnosis of brain tumours, biochemical imaging is better suited for tissue characterisation. The identification of a tumoural mass and the assessment of its size and vascularisation are best achieved with X-ray CT and MRI, while biochemical imaging can provide additional information that is crucial for tumour classification, differential diagnosis and follow-up. As the assessment of variables such as water content, appearance of cystic lesions and location of the tumour are largely irrelevant for tissue characterisation, a number of probes have been employed for the assessment of the biochemical features of tumours. Since biochemical changes may be related to the growth rate of cancer cells, they can be thought of as markers of tumour cell proliferation. Biochemical imaging with radionuclides of processes that occur at a cellular level provides information that complements findings obtained by anatomical imaging aimed at depicting structural, vascular and histological changes. This review focusses on the clinical application of anatomical brain imaging and biochemical assessment with positron emission tomography, single-photon emission tomography and MRS in the diagnosis of primary brain tumours, as well as in follow-up.

show abstract

Measurement of in vivo glucose transport from blood to tissue of experimentally-induced glioma in rat brain

Cited by 8 publications

References 32 publications

Immunocytochemical expression of the blood—brain barrier glucose transporter (GLUT‐1) in neural transplants and brain wounds

Immunocytochemical expression of the blood—brain barrier glucose transporter (GLUT‐1) in neural transplants and brain wounds

Pr�operative Bildgebung

Anatomical and biochemical investigation of primary brain tumours

Contact Info

Product

Resources

About